Blanco, Shulamite A.

HRN: 19-02-19  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/23/2023
CEFUROXIME 500MG (TAB)
06/23/2023
06/30/2023
PO
500mg
BID X 7 Days
2nd Degree RMLE; Leukocytosis; UTI
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: